SecBot SecBot
8-K ·Filed Jul 27, 2026

FBRX

Forte Biosciences, Inc.
BULLISH
Impact 8/10
Horizonweeks Processed3mo ago SEC0001193125-26-316766
8-K material event: Items 1.01
Actionable Insight ▲ Bullish

The key risk to closing is HSR antitrust review, though the transaction is not subject to a financing condition. Monitor for any competing bids during the go-shop period and the Schedule 14D-9 filing for the fairness opinion details.

DirectionBullish
Confidencehigh
Horizonweeks

Drug in focus

FB102

● Neutral Named in this 8-K
Impact
Phase
Phase 1b (proof-of-concept completed); Phase 2 (celiac disease) ongoing
Time to market
Likely 3-5+ years from 2026, pending Phase 2 celiac readout and Phase 3 development. FB102 is currently in Phase 1b/2-stage development with argenx's resources expected to accelerate the pipeline post-acquisition.
Next catalyst
None dated

What to watchFor ARGX investors, FB102 is a bolt-on pipeline asset that adds long-term optionality but is not a near-term binary driver given argenx's ~$53B market cap and $1.5B H1 2026 VYVGART revenue. Watch for Phase 2 celiac disease readout (H2 2026) and the deal closing (expected by late Q3). For FBRX holders, the stock trades near the $77 offer price, the arbitrage spread hinges on antitrust clearance and deal timing.

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$76.50
T+0 close · Jul 27, 2026 · via day close
Latest settled
+0.59%
T+20 · $76.95
Vs SPY
−2.71%
α at T+20
Next horizon
T+60
due 28d ago
  1. T+0 · Jul 27 $76.50entry
  2. T+1 · 4mo ago +0.20%α −0.04% · $76.65
  3. T+5 · 4mo ago +0.13%α −0.94% · $76.60
  4. T+20 · 3mo ago +0.59%α −2.71% · $76.95
  5. T+60 · due 28d ago Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Forte Biosciences (FBRX) has entered into a definitive merger agreement to be acquired by argenx (ARGX) for $77.00 per share in cash, representing a total equity value of approximately $2.2 billion. The transaction will proceed via a tender offer followed by a merger under Section 251(h) of the DGCL, with the Forte board unanimously recommending the offer. The deal provides a substantial premium to recent trading levels and is expected to close in Q3 2026, funded entirely from argenx's cash on hand, with no financing condition.

Key Financial Metrics

Deal Value
$2.2B
Premium
86%
Deal Type
merger

Key Facts

  • argenx to acquire Forte Biosciences for $77.00 per share in cash, total equity value ~$2.2 billion
  • Premium of approximately 86% to Forte's VWAP since reporting positive Phase 1b vitiligo data on July 9, 2026
  • Transaction structured as a tender offer for a majority of shares, followed by a merger under DGCL Section 251(h)
  • Forte's lead program is FB102, a first-in-class anti-CD122 antibody with clinical proof-of-concept in vitiligo and celiac disease
  • Deal expected to close in Q3 2026, subject to regulatory approval (HSR) and minimum tender condition of >50% of shares
  • Termination fee of $65 million payable by Forte under specified circumstances
  • Support agreements in place with directors and executive officers holding ~1% of outstanding shares
  • Transaction not subject to a financing condition; funded entirely from argenx's cash on hand

Financial Impact

Total equity value of approximately $2.2 billion, or $77.00 per share in cash

acquisition premiumshare price

Risk Factors

  • Potential competing acquisition proposal triggering a termination fee
  • Regulatory delay or failure to obtain HSR clearance
  • Stockholder litigation challenging the transaction
  • Failure to meet the minimum tender condition of >50% of shares

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-316766
Document: d31466dex101.htm0001193125-26-316766
Document: d31466d8k.htm0001193125-26-316766
Document: d31466dex991.htm0001193125-26-316766
Document: 0001193125-26-316766-index-headers.html0001193125-26-316766
Document: 0001193125-26-316766-index.html0001193125-26-316766
Document: 0001193125-26-316766.txt0001193125-26-316766

Track record

15 reports on FBRX

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +39.79% at T+60 after the Apr 8, 2026 report. 3 of 6 went positive at some point.

Filters
  1. Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry price pending
  2. Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry price pending
  3. Nov 4, 202612d ago SC 13G/A Bearish 4/10 No price data
  4. Sep 2, 202610w ago EFFECT Bearish 7/10 Entry $76.99 settles Nov 27
  5. Sep 2, 202610w ago EFFECT Bearish 6/10 Entry $76.99 settles Nov 27
  6. Aug 27, 202611w ago 25-NSE Bearish 9/10 Entry $76.99 settles Nov 20
  7. Jul 27, 202616w ago 8-K Bullish 8/10 Viewing Entry $76.50 No price data
  8. Jun 11, 202622w ago EFFECT Bearish 6/10 Entry $17.40 No price data
  9. Jun 5, 202623w ago S-3/A Bearish 6/10 Entry $15.67 No price data
  10. Jun 2, 202623w ago S-3 Bearish 6/10 Entry $17.00 to $76.99 ▼ −352.88% −350.38% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens Wed (9h 57m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 27, 2026